Patient and caregiver assessment of perceived benefits from clinical use of amyloid PET imaging (P6.108)

Conclusions:Patients and caregivers supported the use of amyloid PET in clinical practice and reported significant benefits of having such information for future planning.Study Supported by: NIA R01 AG040770, NIA K02 AG048240, NIA P30 AG010133 and the Easton Consortium for Alzheimer Drug Discovery and Biomarker Development.Disclosure: Dr. Mustafa has nothing to disclose. Dr. Rabinovici has received personal compensation for activities with Eisai, Roche, Lundbeck, and Putnam as a speaker or consultant. Dr. Rabinovici has received research support from NIH, Alzheimer's Association, Tau Consortium, American College of Radiology, Michael J Fox Foundation, Association for Frontotemporal Degneration, Avid Radiopharmaceuticals/Eli Lilly, GE Healthcare, and Piramal Imaging. Dr. Dickerson has received personal compensation for activities with Merck as a consultant. Dr. Dickerson has received personal compensation in an editorial capacity for Neuroimage: clinical. Dr. Carrillo has nothing to disclose. Dr. Glazier has received personal compensation in an editorial capacity for Springer Publishing. Dr. Gao has nothing to disclose. Dr. Tierney has nothing to disclose. Dr. Fargo has nothing to disclose. Dr. Brosch has nothing to disclose. Dr. Austrom has nothing to disclose. Dr. De Santi has received personal compensation for activities with Piramal Pharma as an employee. Dr. Clark has nothing to disclose. Dr. Apostolova received personal compensation for activities with Eli Lilly and Pira...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Mustafa, R., Rabinovici, G., Dickerson, B., Carrillo, M., Glazier, B., Gao, S., Tierney, M., Fargo, K., Brosch, J., Austrom, M., De Santi, S., Clark, D., Apostolova, L. Tags: Aging and Dementia Poster Discussion Session: Novel Approaches in Neurodegenerative Diseases: Genetics, Biomarkers, and Therapies Source Type: research